Solvonis Therapeutics plc

SVNS.L · LSE
Analyze with AI
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Operating Activities
Net Income-£335-£626-£1,994
Dep. & Amort.£0£57£83
Deferred Tax£0£0£0
Stock-Based Comp.£146£7£369
Change in WC£25£73-£228
Other Non-Cash£15£66£1,425
Operating Cash Flow-£149-£423-£345
Investing Activities
PP&E Inv.£0-£4£21
Net Acquisitions£0£0£0
Inv. Purchases£0-£13£0
Inv. Sales/Matur.£0£0£0
Other Inv. Act.-£20£0-£16
Investing Cash Flow-£20-£17£5
Financing Activities
Debt Repay.£0£0£0
Stock Issued£41£112£0
Stock Repurch.£0£0£0
Dividends Paid£0£0£0
Other Fin. Act.-£41£312£0
Financing Cash Flow£0£312£0
Forex Effect-£14£0-£27
Net Chg. in Cash-£183£27-£367
Supplemental Information
Beg. Cash£940£155£522
End Cash£757£27£155
Free Cash Flow-£149-£427-£324